Summary
Loss of DNA mismatch repair has been observed in a variety of human cancers. Recent studies have shown that loss of DNA mismatch repair results in resistance to cisplatin but not oxaliplatin, suggesting that the mismatch repair proteins serve as a detector for cisplatin but not oxaliplatin adducts. To identify the signal transduction pathways with which the detector communicates, we investigated the effect of loss of DNA mismatch repair on activation of known damage-responsive pathways, and recently reported that cisplatin differentially activates c-Jun NH2-terminal kinase (JNK) and c-Abl in repair-proficient vs.-deficient cells. In the current study, we directly compared differential activation of these pathways by cisplatin vs. oxaliplatin. The results confirm that cisplatin activates JNK kinase 5.7 ± 1.5 (s.d.)-fold more efficiently in DNA mismatch repair-proficient than repair-deficient cells, and that the c-Abl response to cisplatin is completely absent in DNA mismatch repair-deficient cells. In contrast, there was no detectable activation of the JNK or c-Abl kinases in DNA mismatch repair-proficient or -deficient cells exposed to oxaliplatin. The present study demonstrates that, despite the similarity of the adducts produced by cisplatin and oxaliplatin, they appear to be recognized by different detectors. The DNA mismatch repair system plays an important part in the recognition of cisplatin adducts, and activation of both the JNK and c-Abl kinases in response to cisplatin damage is dependent on the detector function of the DNA mismatch repair proteins. In contrast, this detector does not respond to oxaliplatin adducts.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. & Howell, S. B. (1996). Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090.
Aebi, S., Fink, D., Gordon, R., Kim, H. K., Zheng, H., Fink, J. L. & Howell, S. B. (1997). Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 3: 1763–1767.
Baskaran, R., Chiang, G. G. & Wang, J. Y. J. (1996). Identification of a binding site in c-Abl tyrosine kinase for the C-terminal repeated domain of RNA polymerase II. Mol Cell Biol 16: 3361–3369.
Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M. B. & Wang, J. Y. J. (1997). Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387: 516–519.
Cavigelli, M., Dolfi, F., Claret, F. X. & Karin, M. (1995). Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14: 5957–5964.
Chaney, S. G. (1995). The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand. Int J Oncol 6: 1291–1305.
Chen, Z., Naito, M., Mashima, T. & Tsuruo, T. (1996). Activation of actin-cleavable interleukin 1-converting enzyme (ICE) family protease CCP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Cancer Res 56: 5224–5229.
Christian, M. C. (1992). The current status of new platinum analogs. Semin Oncol 19: 720–733.
Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M. & Davis, R. J. (1994). JNK1: a protein kinase stimulated by UV light and Ha-ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025–1037.
Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J. & Davis, R. J. (1995). Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267: 682–685.
Duckett, D. R., Drummond, J. T., Murchie, A. I. H., Readon, J. T., Sancar, A., Lilley, D. M. J. & Modrich, P. (1996). Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 93: 6443–6447.
Eastman, A. (1990). Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275–280.
Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D. & Howell, S. B. (1996). The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881–4886.
Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T-P, Nehmé, A., Christen, R. D., Haas, M., Macleod, C. L. & Howell, S. B. (1997). In vitro and In vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 53: 1841–1845.
Fishel, R. & Wilson, T. (1997). MutS homologs in mammalian cells. Curr Opin Genet Dev 7: 105–113.
Gupta, S., Campbell, D., Derijard, B. & Davis, R. J. (1995). Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389–393.
Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R. & Koi, M. (1995). Evidence for a connection between the mismatch repair system and the G2cell cycle checkpoint. Cancer Res 55: 3721–3725.
Hibi, M., Lin, A., Smeal, T., Minden, A. & Karin, M. (1993). Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7: 2135–2148.
Kat, A., Thilly, W. G., Fang, W., Longley, M. J., Li, G. & Modrich, P. (1995). An alkylation–toleration, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424–6428.
Kelland, L. R. (1993). New platinum antitumor complexes. Crit Rev Oncol Hematol 15: 191–219.
Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R. & Kufe, D. W. (1995). Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785–788.
Kharbanda, S., Pandey, P., Jin, S., Inoue, S., Bharti, A., Yan, Z-M, Weicheselbaum, R., Weaver, D. & Kufe, D. (1997). Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386: 732–735.
Kipreos, E. T. & Wang, J. Y. J. (1992). Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 256: 382–385.
Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A. & Boland, C. R. (1994). Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reducesN-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308–4312.
Kolodner, R. (1996). Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 10: 1433–1442.
Liu, Z-G, Baskaran, R., Lea-Chou, E. T., Wood, L. D., Chen, Y., Karin, M. & Wang, J. Y. J. (1996a). Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384: 273–276.
Liu, Z-G, Hsu, H., Goeddel, D. V. & Karin, M. (1996b). Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cell 87: 565–576.
Los, G., Mutsaers, P. H., Ruevekamp, M. & McVie, J. G. (1990). The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett 51: 109–117.
Mattioni, T., Jackson, P. K., van Huijsduijnen, OB-H & Picard, D. (1995). Cell cycle arrest by tyrosine kinase Abl involves altered early mitogenic response. Oncogene 10: 1325–1333.
Mello, J. A., Acharya, S., Fishel, R. & Essigmann, J. M. (1996). The mismatch-repair protein hMSH2 binds selectivity to DNA adducts of the anticancer drug cisplatin. Chem Biol 3: 579–589.
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Woodrich, M., Campbell, H., Mayo, J. & Boyd, M. (1991). Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757–766.
Nehme, A., Rajasekaran, B., Aebi, S., Fink, D., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B. & Christen, R. D. (1997). Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 57: 3253–3257.
Orth, K., Hung, J., Gazdar, A., Bowcock, A., Mathis, J. M. & Sambrook, J. (1994). Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA 91: 9495–9499.
Saris, C. P., van de Vaart, P. J. M., Rietbroek, R. C. & Blommaert, F. A. (1996). In vitroformation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17: 2763–2769.
Sawyers, C. L., McLaughlin, J., Goga, A., Havlik, M. & Witte, O. (1994). The nuclear tyrosine kinase c-abl negatively regulates cell growth. Cell 77: 121–131.
Schmidt, W. & Chaney, S. G. (1993). Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53: 799–805.
Shafman, T., Khanna, K. K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D. & Lavin, M. F. (1997). Interaction between ATM protein and c-Abl in response to DNA damage. Nature 387: 520–523.
Skehan, P., Storeng, R., Scudiero, D., Monks, A., Mcmahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S. & Boyd, M. R. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107–1112.
Umar, A., Boyer, J. C., Thomas, D. C., Nguyen, D. C., Risinger, J. I., Boyd, J., Ionov, Y., Perucho, M. & Kunkel, T. A. (1994). Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 269: 14367–14370.
Umar, A., Koi, M., Risinger, J. I., Glaab, W., Tindall, K. R., Kolodner, R., Boland, C. R., Barrett, J. C. & Kunkel, T. A. (1997). Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine-resistance and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 57: 3949–4955.
Wang, J. Y. J. (1993). Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev 3: 35–43.
Woynarowski, J. M., Chapman, W. G., Napier, C. & Raymond, E. (1997). Oxaliplatin effects on naked and intracellular DNA. Proc Am Assoc Cancer Res 38: 311
Yuan, Z. M., Huang, Y., Ishiko, T., Kharbanda, S., Weichselbaum, R. & Kufe, D. (1997). Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 94: 1437–1440.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nehmé, A., Baskaran, R., Nebel, S. et al. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer 79, 1104–1110 (1999). https://doi.org/10.1038/sj.bjc.6690176
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690176
Keywords
This article is cited by
-
MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway
BMC Cancer (2018)
-
Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy
Cancer Chemotherapy and Pharmacology (2016)
-
GADD45α modulates curcumin sensitivity through c-Abl- and JNK-dependent signaling pathways in a mismatch repair-dependent manner
Molecular and Cellular Biochemistry (2016)
-
DNA damage response in cisplatin-induced nephrotoxicity
Archives of Toxicology (2015)
-
In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors
Cancer Chemotherapy and Pharmacology (2008)